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Abstract
Background: A care gap exists between recommendations and practice regarding the diagnosis and treatment of
osteoporosis in fracture patients. The current study was designed to determine rates and predictors of in-hospital
diagnosis and treatment of osteoporosis in patients admitted with fragility hip fractures, and to assess differences in these
rates since the outset of the multipronged "Fracture? Think Osteoporosis" (FTOP) Program, which includes education
of geriatrics and rehabilitation teams.
Methods: This is a retrospective cohort study conducted with data from two Hamilton, Ontario, university-based
tertiary-care hospitals, and represents a follow-up to a previous study conducted 8 years earlier. Data pertaining to all
354 patients, age >/= 50, admitted between March 2003 and April 2004, inclusive, with a diagnosis of fragility hip fracture
were evaluated. Twelve patients were excluded leaving 342 patients for analysis, with 75% female, mean age 81.
Outcomes included: Primary – In-hospital diagnosis of osteoporosis and/or initiation of anti-resorptive treatment ("new
osteoporosis diagnosis/treatment"). Secondary – In-hospital mortality, BMD referrals, pre-admission osteoporosis
diagnosis and treatment.
Results: At admission, 27.8% of patients had a pre-existing diagnosis of osteoporosis and/or were taking anti-resorptive
treatment. Among patients with no previous osteoporosis diagnosis/treatment: 35.7% received a new diagnosis of
osteoporosis, 21% were initiated on anti-resorptive treatment, and 14.3% received a BMD referral. The greatest
predictor of new osteoporosis diagnosis/treatment was transfer to a rehabilitation or geriatrics unit: 79.5% of
rehabilitation/geriatrics versus 18.5% of patients receiving only orthopedics care met this outcome (p < 0.001).
Conclusion: New diagnosis of osteoporosis among patients admitted with hip fracture has improved from 1.8% in the
mid 1990's to 35.7%. Initiation of bisphosphonate therapy has likewise improved from 0% to 21%. Although multiple
factors have likely contributed, the differential response between rehabilitation/geriatrics versus orthopedics patients
suggests that education of the geriatric and rehabilitation teams, including one-on-one and group-based sessions,
implemented as part of the FTOP Program, has played a role in this improvement. A significant care gap still exists for
patients discharged directly from orthopedic units. The application of targeted inpatient and post-discharge initiatives,
such as those that comprise the entire FTOP Program, may be of particular value in this setting.
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Background
Hip fractures are the most serious consequence of oste-
oporosis due to the associated morbidity, mortality, and
financial costs [1]. It is estimated that the lifetime risk of a
hip fracture for a Caucasian woman age 50 or older is 17%
[2]. Hip fractures are associated with functional impair-
ment [3], poor health-related quality of life [4], institu-
tionalization [5,6] and mortality [6-8]. By the year 2041,
the annual costs related to hip fractures in Canada are pro-
jected to be 2.4 billion dollars [9].
Even a minor fracture significantly increases future frac-
ture risk [10]. However, rates of osteoporotic fractures can
be reduced with appropriate therapy [11-14]. The Oste-
oporosis Canada 2002 clinical practice guidelines state
that individuals who have sustained a fragility fracture are
at high risk for future osteoporotic fractures and require
bone mineral density (BMD) measurement and evalua-
tion for therapy [15]. Similarly, the (U.S.) National Oste-
oporosis Foundation recommends that all
postmenopausal women with a history of fragility fracture
receive an anti-resorptive agent in addition to adequate
calcium plus vitamin D intake [16].
Despite these guidelines [16,17], a recognized care gap
exists between recommendations and practice with regard
to the diagnosis and treatment of osteoporosis in individ-
uals with fractures [18-20]. In Hamilton, Ontario, a prior
observational study between April 1st  1995, through
March 31st, 1996, involving 504 patients, revealed very
poor recognition of osteoporosis by the time of discharge
post fragility hip fracture [6].
In 2003, a city-wide initiative was launched in Hamilton,
Ontario, to reduce the rate of future fractures in patients
presenting with fragility fractures by improving oste-
oporosis recognition and treatment. The overall initiative
is known as the "Fracture? Think Osteoporosis" (FTOP)
Program, and includes osteoporosis education of rehabil-
itation and geriatrics teams, relevant to the diagnoses and
treatment of patients in the immediate post-fracture
period. Specifically, prior to the present study, this educa-
tion comprised a one-hour problem-based Continuing
Medical Education event and written materials, and was
offered to geriatrics and rehabilitation faculty and resi-
dents. Further, the geriatrics and rehabilitation faculty
were provided with "academic detailing" [21] by one of
the authors (AP). This consisted of one-on-one review of
individual practices with respect to osteoporosis diagnosis
and treatment, with subsequent tailored feedback and
education. This education occurred in the year prior to the
current analysis. Other components of the FTOP program
target outpatient post-fracture care specifically, and thus
have no direct impact on the in-hospital care of patients
admitted with fracture.
To determine if the education of geriatrics and rehabilita-
tion physicians and residents has had possible effects on
inpatient osteoporosis care by the time of discharge, we
conducted a 14-month chart review for 2003–2004, and
compared data with those obtained at the same hospitals
in the mid 1990's [6]. The secondary objectives of the cur-
rent study were to examine: predictors of new osteoporo-
sis diagnosis and/or anti-resorptive treatment, pre-
admission osteoporosis status, in-hospital mortality, and
BMD referral.
Methods
Patients
This was a retrospective cohort study of patients admitted
to two Hamilton (Ontario, Canada) university-based ter-
tiary-care hospitals with fragility hip fracture. Charts were
reviewed for all 354 patients, age 50 years or older, admit-
ted between March 1st 2003 and April 30th 2004, with a
diagnosis of fragility hip fracture [22]. ICD-9 codes were
used to determine patients admitted with hip fracture,
and fragility fractures were defined as those resulting from
minimal trauma, specifically, fall from a standing height
or less [23] and were determined through chart review.
Patients with pathological fractures secondary to malig-
nancy or intrinsic bone disease (e.g. Paget's disease) were
excluded. Patients were also excluded if they were trans-
ferred to an outside hospital for definitive treatment. Alto-
gether, 12 charts were excluded (Figure 1) and the final
study cohort comprised 342 patients.
Independent Variables
Using a standardized data collection tool, data were
abstracted from two electronic clinical databases used at
Hamilton Health Sciences. Data obtained were: age, sex,
previous residence, hospital length of stay (acute and
total), comorbidities, medications on admission, transfers
to geriatrics or rehabilitation, and final discharge location
(i.e. community, LTC facility). Baseline co-morbidities,
including osteoporosis, and medication data were based
on the physician admission notes. Hereafter, "previous
osteoporosis diagnosis/treatment" refers to the combina-
tion of osteoporosis diagnosis and/or anti-resorptive ther-
apy based on the admission note.
As a final independent variable, reports for all radiographs
performed during the index admission were examined for
any "radiographic evidence of bone loss" by the radiolo-
gist defined as mention of additional fractures (i.e. any
fracture other than the index fracture) or notation of
"demineralization", "osteopenia", "osteoporosis" or
other suggestion of low bone mass.
Outcome Variables
The primary outcome (referred to hereafter as "new oste-
oporosis diagnosis/treatment") was a combination of twoBMC Geriatrics 2009, 9:28 http://www.biomedcentral.com/1471-2318/9/28
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variables: 1) a new diagnosis of osteoporosis, AND/OR 2)
initiation of anti-resorptive therapy (bisphosphonate,
raloxifene, calcitonin or hormone replacement therapy
(HRT)). These events must have occurred after admission
for the index hip fracture and up until the time of final dis-
charge (including final documentation) from an ortho-
pedic, rehabilitation or geriatric service. A new diagnosis
was considered a notation of "osteoporosis" anywhere in
the chart by a doctor or clinical clerk at any point during
the hospital stay. Initiation of anti-resorptive therapy was
similarly determined and had to represent a new prescrip-
tion as compared with admission. Initiation of calcium
and vitamin D were determined in the same manner.
Additional outcomes of interest were referral for BMD (i.e.
performed, booked, or suggested) and death during the
inpatient stay.
Statistical Analyses
Between-group comparisons were performed using Pear-
son chi-square for categorical variables, and independent
samples t-tests for continuous variables. For the latter,
equal variances were assumed unless the respective p val-
ues for Levene's test were < 0.05. Rates/predictors of new
osteoporosis diagnosis/treatment were examined only for
patients with no  previous osteoporosis diagnosis/treat-
ment and who survived to discharge. New osteoporosis
diagnosis/treatment rates were nearly identical for
patients transferred to rehabilitation versus geriatrics, thus
these patients were considered as one group. Multivaria-
ble logistic regression modeling was performed to deter-
mine the association between new osteoporosis
diagnosis/treatment and potential demographic/clinical
predictor variables (i.e. demographics, medications,
comorbidities, "radiographic evidence of bone loss", and
hospital stay variables). All clinically important variables
(age, sex, previous fracture, oral corticosteroid use, "radi-
ographic evidence of bone loss" and other variables with
a significant impact in univariate analyses (p < 0.05) were
entered in a backward stepwise multivariable logistic
regression model and were removed at p = 0.10. Separate
logistic regression analyses were also conducted for
patients transferred to rehabilitation/geriatrics versus
those receiving only orthopedics care. Odds ratios (ORs)
and 95% confidence intervals are reported for predictor
variables. Statistical significance was defined as p < 0.05.
Statistical analyses were performed with SPSS software
13.0® (SPSS Inc., Chicago IL).
Breakdown of patients included/excluded Figure 1
Breakdown of patients included/excluded.
Death prior 
to discharge:
n=6
354 consecutive hip fracture 
patients (50 years+)
12 excluded:
Malignancy (4)
Trauma (2)
Paget’s Disease (5)
Transfer to Outside Facility (1)
Total Study Cohort: N= 342 
256 Women
86 Men
No Previous OP Diagnosis/Treatment: n=247
168 Women
79 Men
Orthopaedic Care 
Only
n=151
Transfer to 
Rehab/Geriatrics:
n=73
Death prior 
to discharge:
n=23
Previous OP Diagnosis/Treatment: n=95
88 Women
7 Men
Orthopaedic Care 
Only
n=59
Transfer to 
Rehab/Geriatrics:
n=30
Survived to discharge:
n=89
Survived to discharge:
n=224BMC Geriatrics 2009, 9:28 http://www.biomedcentral.com/1471-2318/9/28
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Ethics approval for this study was granted by the Hamil-
ton Health Sciences/McMaster University Faculty of
Health Sciences Research Ethics Board.
Results
Of 342 eligible patients, 86 were male (25%) and 256
were female (75%). The mean age at admission was 81.0
years (SD 10.2). The mean ages of males and females were
not significantly different (Table 1). The overall in-hospi-
tal mortality rate was 8.5%, with 313 patients surviving to
final discharge.
Previous osteoporosis diagnosis/treatment
At admission, 28% of the sample (8% of men and 34% of
women) had a previous osteoporosis diagnosis/treat-
ment. One-hundred-twelve patients (33%) had a prior
fracture other than the index hip fracture. Of those with a
prior fracture, 31% were taking anti-resorptive therapy
and 18% were taking calcium and/or vitamin D (calcium
17%, vitamin D 9%). Table 1 summarizes the characteris-
tics of the study cohort overall and stratified by previous
osteoporosis diagnosis/treatment.
New osteoporosis diagnosis and treatment
Of the 247 patients with no previous osteoporosis diagno-
sis/treatment, 224 (91%) survived to discharge (Figure 1).
As displayed in Table 2, of all patients with no previous
osteoporosis diagnosis/treatment: 35.7% received a new
diagnosis of osteoporosis, 21% were initiated on anti-
resorptive treatment, and 14.3% received a BMD referral
while in hospital. Three patients had osteopenia listed at
the time of admission; two of these three received a new
Table 1: Demographic and clinical characteristics, No. (%) of patients*
Previous Osteoporosis Diagnosis/Treatment
Overall Cohort (n = 342)
No
(n = 247)
Yes
(n = 95)
P†
Demographic
Female 256 (74.9) 168 (68.0) 88 (92.6) <0.001
Age in years; Mean (SD)‡ 81.0 (10.2) 80.9 (10.6) 81.2 (9.0) 0.835
Male 79.4 (10.3)
Female 81.5 (10.1)
Previous Residence:
Community 255 (74.6) 182 (73.7) 73 (76.8) 0.296
Admission Medications
Calcium and/or Vitamin D 53 (15.5) 24 (9.7) 29 (30.5) <0.001
Calcium 48 (14.0) 24 (9.7) 24 (25.3) <0.001
Vitamin D 31 (9.1) 9 (3.6) 22 (23.2) <0.001
Any Anti-resorptive ≠ 67  (19.6) - 67  (70.5) n/a
Bisphosphonate ¶ 60 (17.5) - 60 (63.2) n/a
Raloxifene 3 (0.9) - 3 (3.2) n/a
Calcitonin 0 - 0 n/a
HRT 6 (1.8) - 6 (6.3) n/a
Comorbidities
Prior Fracture 112 (32.7) 67 (27.1) 45 (47.4) <0.001
Cognitive impairment 117 (34.2) 88 (35.6) 29 (30.5) 0.373
Prior stroke 74 (21.6) 53 (21.5) 21(22.1) 0.896
Parkinson's disease 13 (3.8) 9 (3.6) 4 (4.2) 0.806
Frequent falls 54 (15.8) 38 (15.4) 16 (16.8) 0.741
In-Hospital
Acute care stay length in days; Mean (SD) 20.6 (19.4) 21.2 (20.7) 19.0 (15.5) 0.296
Total stay length in days§; Mean (SD) 31.2 (27.8) 31.4 (28.3) 30.6 (26.5) 0.795
Post-operative Care:
Orthopedics Only 238 (69.6) 173 (70.0) 65 (68.4) 0.771
Rehabilitation/Geriatrics 104 (30.4) 74 (30.0) 30 (31.6)
Radiographic Evidence £ 90 (26.3) 60 (24.3) 30 (31.6) 0.170
Death prior to discharge 29 (8.5) 23 (9.3) 6 (6.3) 0.373
SD = Standard Deviation NS = not significant; N/A = not applicable; OP = Osteoporosis
*Unless stated otherwise. ‡No significant difference between men and women. ≠ Two patients were taking raloxifene and a bisphosphonate. 
¶Alendronate, Etidronate, or Risedronate £Radiographic evidence of bone loss (see text). §Includes orthopedic service plus any transfers to 
rehabilitation or geriatrics services. †Comparison of 'no previous osteoporosis diagnosis/treatment' with 'previous osteoporosis diagnosis/
treatment'.  BMC Geriatrics 2009, 9:28 http://www.biomedcentral.com/1471-2318/9/28
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osteoporosis diagnosis/treatment (data not shown).
Transfer to rehabilitation/geriatrics strongly influenced
rates of diagnosis, treatment and BMD referral. Seventy
eight percent of patients transferred to rehabilitation/ger-
iatrics were initiated on calcium and/or vitamin D (versus
13% otherwise), 59% were initiated on an anti-resorptive
agent (versus 2.6%), and 29% received a BMD referral
(versus 7.3%; only one of the two hospitals has access to
BMD for inpatients; see Table 2). Overall, 79.5% of reha-
bilitation/geriatrics patients versus 18.5% of orthopedics
only patients received a new osteoporosis diagnosis/treat-
ment (p < 0.001).
Predictors of new osteoporosis diagnosis/treatment
In univariate analyses, transfer to rehabilitation/geriatrics
was a strong predictor of new osteoporosis diagnosis/
treatment (OR = 17.0; 95% CI: 8.4–34.2). Factors associ-
ated with a decreased chance of this outcome were:
dementia/cognitive impairment (OR = 0.39; 95% CI: 0.21
– 0.72), previous residence in long-term care (LTC) (OR =
0.10; 95% CI: 0.04–0.26), and final discharge to LTC (OR
= 0.25; 95% CI: 0.14–0.44). Acute stay length was also sig-
nificantly higher among patients receiving a new oste-
oporosis diagnosis/treatment than those who did not
(26.8 days versus 17.9 days; p = 0.002). Age, gender, pre-
vious fracture, oral corticosteroid use, and "radiographic
evidence of bone loss" were not significantly different
between patients with a new osteoporosis diagnosis/treat-
ment and those without.
Results of multivariable logistic regression analyses are
presented in Table 3. Backward elimination identified
acute care length of stay and transfer to rehabilitation/ger-
iatrics as significant predictors of new osteoporosis diag-
nosis/treatment. Although not significant in the final
multivariable model, females were more likely to be diag-
nosed and patients discharged to LTC were less often diag-
nosed.
When the orthopedics only group (n = 151) was exam-
ined separately in multivariable analyses, acute care stay
length (OR = 1.04; 95% CI: 1.01–1.05) and female sex
(OR = 4.29; 95% CI: 1.20–15.35) were significant predic-
tors of new osteoporosis diagnosis/treatment. Among
patients transferred to rehabilitation/geriatrics, no factors
were predictive of this outcome in multivariable analyses.
None of the patients in this group had resided in LTC
prior to admission; 12 (16.4%) were discharged to LTC.
Discussion
The present study of fragility hip fracture patients demon-
strated that involvement of a geriatric or rehabilitation
medical team was associated with considerably improved
osteoporosis assessment and management. A recent rand-
omized controlled trial has demonstrated the value of a
case manager in post-fracture osteoporosis diagnosis and
treatment, for instance increasing bisphosphonate use
from 22% in the control group to 51% in the treatment
group at 6 months [24]. In the present study 56.2% of
patients transferred to rehabilitation/geriatrics were
started on a bisphosphonate during the index admission.
Our study shows that in-hospital osteoporosis diagnosis
and treatment has improved substantially in Hamilton,
Ontario since the mid-1990's when a similar analysis was
conducted at the same hospitals, involving 504 patients,
age 50 and older, over a one year period [6]. In the previ-
ous study, diagnosis was made in only 1.8% of patients,
versus 35.7% in the current study, representing an overall
rate of new diagnosis of 34%. Discharge medication
Table 2: In-hospital rates of new osteoporosis diagnosis, treatment initiation, and BMD referral, No. (%) of patients*
Post-operative Care
Characteristic Total*
(n = 224)
Orthopedics Only
(n = 151)
Transfer to Rehabilitation/Geriatrics
(n = 73)
P†
In-hospital Osteoporosis Diagnosis 80 (35.7) 27 (17.9) 53 (72.6) <0.001
BMD referral 32(14.3) 11 (7.3) 21 (28.8) <0.001
Calcium initiated 67 (29.9) 17 (11.3) 50 (68.5) <0.001
Vitamin D initiated 76 (33.9) 19 (12.6) 57 (78.1) <0.001
Calcium and/or Vitamin D initiated 77 (34.4) 20 (13.2) 57 (78.1) <0.001
Any Anti-resorptive initiated 47 (21.0) 4 (2.6) 43 (58.9) <0.001
Bisphosphonate 45 (20.1) 4 (2.6) 41 (56.2)‡ <0.001
Raloxifene 1 (0.4) 0 1 (1.4) 0.149
Calcitonin 2 (0.9) 0 2 (2.7) 0.041
HRT 0 0 0 n/a
New Osteoporosis Diagnosis/Treatment 86 (38.4) 28 (18.5) 58 (79.5) <0.001
*Only patients surviving to discharge with no previous osteoporosis diagnosis/treatment. †Comparison of the 'Orthopedics only' versus 'Transfer 
to Rehabilitation/Geriatrics'. ‡One patient was initiated on calcitonin and a bisphosphonate.BMC Geriatrics 2009, 9:28 http://www.biomedcentral.com/1471-2318/9/28
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review among 141 patients admitted at one site revealed
that no patient was prescribed anti-resorptive treatment in
the previous study [6], versus 21% in this study. Likewise,
17.7% of patients were started on calcium and/or vitamin
D [6], versus 34.4% in the present study.
Rates of treatment initiation and BMD referral in the
present study appear higher than those in some reports. A
retrospective cohort study in the United States (N = 3812
postmenopausal women) demonstrated that fewer than
5% had a BMD measurement either prior to, or in the 6
months following a fragility fracture, and only 5.5% were
prescribed a bisphosphonate [25]. Another American
study found that between 1997 and 2000 only 13% of
those who had experienced hip fractures received supple-
mental calcium, and only 6% received an anti-resorptive
medication [26]. However, the rate of bisphosphonate
prescription in our study was similar to the control arm in
the aforementioned recent Canadian study [27].
Only 31% of patients with a prior fracture (other than the
index fracture) were taking an anti-resorptive medication
at the time of admission. Although it was not possible to
determine what proportion of these were fragility frac-
tures, this is similar to the findings of other studies exam-
ining the treatment of fragility fractures [28-30], and
along with our hospital data, highlights that Canadian
healthcare providers are not adequately recognizing fragil-
ity fractures as a major risk factor for osteoporosis and
future fracture.
In a recent prospective cohort study by Hamel and col-
leagues [31] (non-academic community setting), 30% of
the 1144 patients had a history of prior fractures; how-
ever, they were no more likely than those without a his-
tory of fracture to be taking calcium, vitamin D or a
bisphosphonate prior to BMD testing. Similarly, we found
no significant difference with respect to calcium and vita-
min D use prior to hospitalization in patients with or
without a prior fracture. However, significantly more of
the patients in this study with than without a prior frac-
ture were taking a bisphosphonate (31 versus 14%);
whereas Hamel and colleagues found no difference
between groups (overall only 2% of patients were taking
bisphosphonates) [32].
The finding that the rehabilitation and geriatrics teams
better recognized and treated osteoporosis than did the
Table 3: Predictors of a new osteoporosis diagnosis and/or treatment initiation*
% (No.) with New osteoporosis 
diagnosis/treatment
Unadjusted OR (95% CI) Adjusted OR (95% CI)† P
Age - 1.01 (0.98-1.03) -
Length of Stay (acute care), days - 1.02 (1.01-1.04) 1.03 (1.02-1.05) <0.001
Post-operative Care
Rehabilitation/Geriatrics 79.5% (58) 17.0 (8.4-34.2) 16.1 (7.17-36.2) <0.001
Orthopedics Only 18.5% (28)
Sex
Female 40.8% (64) 1.4 (0.77 – 2.6) 2.12 (0.94-4.77) 0.07
Male 32.8% (22)
Previous Fracture (non-index)
Yes 35.5% (22) -
No 39.5% (64) 0.84 (0.46 – 1.5)
Oral Corticosteroid Use
Yes 28.6% (2) 0.63 (0.12-3.3) -
No 38.7% (84)
Radiographic Evidence €
Yes 42.6% (23) 1.3 (0.68-2.3) -
No 37.1% (63)
Dementia/Cognitive Impairment
Yes 24.7% (19) 0.39 (0.21-0.72) -
No 45.6% (67)
Previous Residence
LTC 8.6% (5) 0.10 (0.04-0.26) -
Community 48.8% (81)
Discharge Location
LTC 22.5% (25) 0.25 (0.14-0.44) 0.51 (0.23-1.13) 0.09
Community 54% (61)
OR = Odds Ratio; CI = Confidence Interval. *Patients with no previous osteoporosis diagnosis or treatment, surviving to discharge (n = 224). 
†Only variables remaining in the final stepwise model. €Radiographic evidence of osteoporosis (see text).BMC Geriatrics 2009, 9:28 http://www.biomedcentral.com/1471-2318/9/28
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orthopedics teams is likely attributable, at least in part, to
the FTOP education program. An education program tar-
geting internists has led to improved recognition of radio-
graphic vertebral fractures with subsequent improvements
in osteoporosis treatment [24]; however, a brief (one
hour) primary care physician education initiative did not
lead to improved BMD use or osteoporosis treatment
[25]. Overall, there is a lack of data in this area, and our
data are promising.
However, it must be acknowledged that issues other than
lack of sufficient educational strategies may well be play-
ing a role on the orthopedics wards. These may include
clinicians' workload and the perceived scope of acute care.
It is also possible that there remains reluctance among the
orthopedics teams to initiate bisphosphonate treatment
due to concern regarding fracture healing. However, this
would not account for the low rates of osteoporosis diag-
nosis or calcium/vitamin D initiation. Furthermore, there
is no evidence that supports bisphosphonates adversely
affect fracture healing [33], something that will be impor-
tant to stress in future educational activities.
Further, given the eight-year span between the prior and
current studies in Hamilton, it is likely that other factors,
including published guidelines [16,34], cost-effectiveness
data [35], pharmaceutical marketing, and changes to
undergraduate and postgraduate training-program curric-
ula also explain a component of the improved rates of
osteoporosis diagnosis and treatment on the geriatrics
and rehabilitation wards.
Our study also suggests bias against new osteoporosis
diagnosis/treatment for residents who were from or dis-
charged to LTC. Given the increased risk for falls and frac-
tures among individuals residing in LTC [36,37],
treatment evaluation in this group should not be over-
looked. Interestingly, baseline rates of diagnosis or treat-
ment (i.e. at admission) of osteoporosis were similar for
LTC and community residents (Table 1). Men with hip
fractures were also less likely to receive a new osteoporosis
diagnosis/treatment, despite an equally important need to
appropriately manage men with osteoporosis [38].
There are several important limitations to this study. The
results are based on data abstracted from medical records,
and are therefore dependent on the completeness of doc-
umentation. The issue of recall bias may be problematic
in terms of patients' reported use of calcium and vitamin
D on admission, and bias would likely be in the direction
of underreporting. Women reporting HRT use may have
been misclassified as having been 'treated for osteoporo-
sis', since most were likely using it for menopausal symp-
toms as opposed to osteoporosis per se. However, only 6
of 342 women were taking HRT at baseline, and no one
was initiated on HRT in hospital. Finally, since this study
only assessed diagnosis and treatment during hospital
admission, data does not reflect the rates of subsequent
evaluation and treatment by their primary care or other
physicians in the community.
Conclusion
Improvements seen in the current study are likely due, at
least in part, to information dissemination strategies that
are incorporated in the "Fracture? Think Osteoporosis"
Program. These strategies include one-on-one education
("academic detailing" [21]) of staff physicians, and group
education involving staff physicians and residents
involved in the inpatient care of individuals admitted
with fracture. The study emphasizes the importance of
addressing particular patient groups, including men, and
individuals being discharged to long-term care facilities. It
also highlights the potential for collaborative teams to
optimize the treatment of patients admitted with fracture;
that is, such teams can help ensure that not only the acute
fracture care is addressed, but also that future fracture pre-
vention is optimized. Future efforts should address barri-
ers to the incorporation of guidelines and best practices in
the care of older adults with fractures, and further examine
the role of multipronged initiatives such as the FTOP Pro-
gram. It will be important to determine the longer-term
effects of such programs on diagnostic, treatment and
clinical outcomes in patients with fragility fracture follow-
ing discharge from acute care.
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